GlassScriptPhysician profile
Sunil K Sharma
NPI 1376604272
$17,338.77
in general payments reported to CMS, 2019-2025
63 companies · $2,895 in 2025
The $2,895 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,928 · 2020: $2,404 · 2021: $2,706 · 2022: $2,259 · 2023: $2,373 · 2024: $1,774 · 2025: $2,895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,041.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,324.19 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $2,045.89 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $1,615.20 | 2019-2025 | |
| Novo Nordisk INC | $1,257.05 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,164.74 | 2019-2025 | Vraylar, Linzess, Viberzi |
| Janssen Pharmaceuticals, INC | $839.72 | 2020-2024 | Xarelto |
| Astellas Pharma US INC | $659.27 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $594.31 | 2019-2025 | |
| Amarin Pharma, INC. | $572.42 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $538.98 | 2019-2025 | Jardiance |
| Abbott Laboratories | $474.11 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $428.69 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $387.96 | 2019-2023 | Verquvo, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $363.42 | 2021-2025 | |
| Amgen INC. | $362.80 | 2019-2025 | Evenity, Repatha, Otezla |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.